Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

OCTA-Directed PDT Triple Therapy for Treatment-Naïve Patients With Exudative Age-Related Macular Degeneration Versus Standard of Care Anti-VEGF(Anti-vascular Endothelial Growth Factor) Monotherapy

Optical Coherent Tomography Angiography (OCTA)-Directed PDT Triple Therapy for Treatment-Naïve Patients with Exudative Age-related Macular Degeneration (ARMD) versus Standard of Care Anti-VEGF Monotherapy

This study is a 48 week, single center, randomized controlled clinical trial. Approximately 150 subjects will be randomized into three separate arms. This study compares the efficacy of standard of care Lucentis (ranibizumab) monotherapy versus OCTA-Directed PDT Triple Therapy with Lucentis (ranibizumab), PDT with Visudyne (verteporfin), and Triescence (triamcinolone acetonide) in treatment-naïve patients with Exudative Age-Related Macular Degeneration. OCTA-Directed PDT Double Therapy with Lucentis (ranibizumab) and PDT with Visudyne (verteporfin) will also be tested to confirm the hypothesis that steroids are necessary.

Inclusion Criteria:

• Willing to give written informed consent
• Willing and able to comply with all study procedures for the duration of the study.
• Presence of Exudative ARMD with evidence of choroidal neovascularization: type 1, 2, and/or 3 on spectral domain OCT, fluorescein angiography, indocyanine green angiogram and optical coherent tomography angiography
• Visual Acuity of 20/25 to 20/400 at screening and baseline visits using an autorefractor or Early Treatment Diabetic Retinopathy Study
• Intraocular pressure less than or equal to 25mmHG
• Females of childbearing potential that are willing to use medically acceptable methods of birth control.

Exclusion Criteria:

• Exudation maculopathies without drusen
• Previous treatment with macular photocoagulation, anti-VEGF medication or PDT with Visudyne
• Myocardial infarction or cerebrovascular accident within the last 6 weeks
• Previous vitrectomy
• Optic neuropathy
• Diabetic retinopathy
• Traction maculopathies
• Allergies to fluorescein and indocyanine, dilating agents or anti-VEGF medications
• Have received previous treatment for ARMD
• Any uncontrolled condition or illness that in the opinion of the investigator makes the subject unsuitable for the study